Sirnaomics to Showcase Data for Lead Product STP705 in Human Squamous Carcinoma Tumor Model at 2020 American Academy of Dermatology Annual Meeting
GAITHERSBURG, Md., March 9, 2020 /PRNewswire/ -- Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that the company's abstract related to preclinical data for lead product candidate STP705 in human squamous carcinoma model has been accepted as an online ePoster for the 2020 American Academy of Dermatology (AAD) Annual Meeting that is being held March 20-24 in Denver, CO.
Abstract title: Effect of TGF- 1/COX-2 small interfering (si)RNA combination product (STP705) on cell viability and tumor growth in a human squamous carcinoma xenograft tumor model in nude mice
Authors: Brian Berman, University of Miami Miller School of Medicine, Miami, FL; Michael Molyneaux, David Evans, and Patrick Lu, Sirnaomics, Inc., Gaithersburg, M.D.
Poster Access: The ePoster will be available online on Friday, March 20 through Sunday, March 22, 2020
"We look forward to sharing the latest research supporting STP705's potential as a future treatment option for patients living with non-melanoma skin cancer," said Patrick Lu, Ph.D., President and CEO of Sirnaomics.
Non-melanoma Skin Cancer (NMSC) represents the most common form of cancer, such as Basal CellCarcinoma and Squamous Cell Carcinoma. According to a 2019 report by Frost & Sullivan, approximately 450,000 cases of NMSC are diagnosed in the US annually. Current RNAi drugs have the potential to provide non-surgical treatment for NMSC with high efficacy and cure rates.
Sirnaomics is currently conducting a Phase IIa clinical trial with STP705 for the treatment of non-melanoma skin cancer. This dose ascending trial is designed to include five cohorts receiving local delivery of STP705. Enrollment has been completed in the first three cohorts and continues in the last two cohorts.
About Sirnaomics, Inc.
Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The company's mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.
CONTACT:
Sirnaomics, Inc.
Michael Molyneaux M.D. MBA
Chief Medical Officer
michaelmolyneaux@sirnaomics.com
Westwicke, an ICR Company
Investors:
Stephanie Carrington
Tel: +1 646 277 1282
Email: Stephanie.Carrington@icrinc.com
Media: Mark Corbae
Tel: +1 203 682 8288
Email: mark.corbae@icrinc.com
SOURCE Sirnaomics, Inc.
